PharMingen

San Diego, United States Founded: 1994 • Age: 32 yrs Acquired By Becton Dickinson
Develops, manufactures and sells high-quality antibodies and reagents for immunology, cell biology, and molecular biology research
Annual revenue $164.7M Latest available
Total funding - Funding intelligence
Employees 653 Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About PharMingen

PharMingen is a company based in San Diego (United States) founded in 1994 was acquired by Becton Dickinson in May 1997. The company has 653 employees as of September 30, 2024. PharMingen operates in a competitive market with competitors including Bio Rad, Siemens Healthineers, Merck, Quanterix and Biocare Medical, among others.

  • Headquarter San Diego, United States
  • Employees 653 as on 30 Sep, 2024
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
    $164.71 M (USD)
    5
    as on Mar 31, 2024
  • Net Profit
    $9.1 M (USD)
    24
    as on Mar 31, 2024
  • EBITDA
    $17.4 M (USD)
    13
    as on Mar 31, 2024
  • Latest Funding Round
  • Investors
  • Employee Count
    653

    as on Sep 30, 2024

  • Acquired by
    Becton Dickinson

    (May 19, 1997)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of PharMingen

Investors in PharMingen

PharMingen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include BD.

All
Institutional
Investor Description Founded Year Domain Location
BD is recognized for providing innovative medical technology solutions.
Founded Year Domain Location

Investments & Acquisitions by PharMingen

Investments

Financial Statements - PharMingen

Pharmingen Comparisons

+
Add Comparison
Available on Premium

Competitors of PharMingen

PharMingen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bio Rad, Siemens Healthineers, Merck, Quanterix and Biocare Medical, among others.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Portfolio of products and services for life science research and clinical diagnostic markets
domain founded_year HQ Location
AI-based medical diagnostics are developed for healthcare applications.
domain founded_year HQ Location
Merck is engaged in science and technology solutions globally.
domain founded_year HQ Location
Assay kits for ultra-sensitive biomarker detection are developed.
domain founded_year HQ Location
Primary antibodies and instruments for immunohistochemistry are manufactured.
domain founded_year HQ Location
Tissue hypothermic storage and cryopreservation freeze media are developed.

Latest news on Pharmingen

Frequently Asked Questions about PharMingen

PharMingen was founded in 1994.

PharMingen is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

As of Sep 30, 2024, the latest employee count at PharMingen is 653.

Annual revenue of PharMingen is $164.71M as on Mar 31, 2024.

PharMingen was founded in 1994 in San Diego, United States, focusing on the biotechnology sector for research tools. Operations involve the development, manufacturing, and distribution of monoclonal antibodies, their conjugates, polyclonal antibodies, protein expression systems, and recombinant proteins targeted at immunology, cell biology, and molecular biology applications. The company was acquired by Becton Dickinson Company in May 1997.

PharMingen's top competitors include Biocare Medical, Merck and Siemens Healthineers.

PharMingen has 1 investor. Key investors include BD.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available